NCT01028248View on ClinicalTrials.gov

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2013

Conditions
Central Retinal Vein Occlusion
Interventions
DRUG

Ranibizumab (Lucentis)

0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally

Trial Locations (3)

93103

California Retina Consultants, Santa Barbara

93309

California Retina Consultants, Bakersfield

93454

California Retina Consultants, Santa Maria

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

California Retina Consultants

OTHER